We are live on ! Find out more

BHST

BioHarvest Sciences

BHST

Market cap $45.6M

2.01 USD

-0.01

0.5%

At close Updated Aug 26, 10:16 AM EDT

1 day

-0.5%

5 days

-1.95%

1 month

-0.99%

3 months

-48.59%

6 months

-57.86%

Year to date

-61.42%

1 year

-77.67%

5 years

-65.04%

10 years

-65.04%

About: BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.

Employees: 89

Consumer Staples Packaged Foods

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 66.7%

Negative 8.3%

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business.

BioHarvest Sciences Q2 Earnings Call Highlights

Proactive Investors

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up 3.8% from a year earlier.

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

Zacks Investment Research

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO business Reports $8.8 million in Q2 revenue, up 3.8% from Q2 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced results from the second quarter and six months of 2026. Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "We are extremely pleased to have announced a manufacturing agreement this morning with our UAE-based fragrance customer that secures commitment to produce a fragrance ingredient that is widely regarded as one of the most valuable fragrance raw materials in the world.

BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update

BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance

Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional collaborations in the high-margin rare fragrance space Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced an exclusive manufacturing and supply agreement that secures production of a rare, endangered, fragrance plant cell culture, extending terms of the original Agreement ("the Agreement") with its existing fragrance partner, an undisclosed* customer based in the United Arab Emirates (UAE). This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.

BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance

BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In addition to presenting, Dr. Rakib will also be participating in one-on-one investor meetings from August 11-12.

BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference

BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide an update on business operations.

BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026

Proactive Investors

BioHarvest lands $1.4M grant for AI-driven plant science

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS (about $1.4 million) grant from the Israel Innovation Authority to fund a new research initiative applying machine learning and computer vision to its plant cell culture programs. The non-dilutive funding, BioHarvest's second grant from the IIA this year, will support integration of data science, chemo-informatics and high-throughput digital sensing into the company's biological development workflows, aiming to move plant cell culture away from trial-and-error methods toward a data-driven optimization framework.

BioHarvest lands $1.4M grant for AI-driven plant science

BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis

Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest's CDMO customers and partners Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest's biological development workflows, thereby accelerating its plant cell culture programs.

BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis

See News Rankings

Price charts implemented using Lightweight Charts™